US heart institute considers exclusive patent license to AntaraCore for heart-rhythm catheter treatment
The National Heart, Lung and Blood Institute, part of the National Institutes of Health, is considering giving AntaraCore, Systems, Inc., a Dover, Delaware company, an exclusive license to a set of patent applications. The patents cover a catheter-based method for treating dangerous heart rhythm problems in people. An exclusive license means only the named company could use these inventions commercially.
This summary was generated by AI; the official source prevails.
What does it mean?
The government heart research body is thinking about letting one company be the only one allowed to use a new heart treatment method. The treatment uses a thin tube inserted into the body to treat dangerous irregular heartbeats. This is only a proposal for now, not a final decision.
Who is affected?
Patients with dangerous irregular heartbeats and companies that might want to develop this heart treatment.